Revised dosing of Ciprofloxacin for patients with impaired renal function: a bioequivalence study

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520379-28-00

Enrollment

Registered

2025-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bacterial infection

Brief summary

Drug exposure in the first 24 hours of treatment (AUC0- 24)

Interventions

DRUGCIPROFLOXACIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Drug exposure in the first 24 hours of treatment (AUC0- 24)	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026